• Explore /
  • Poster
  • / Prognostic impact of 21 Gene Recurrence Score, IHC4, and central grade in high-risk HR+/HER2- early breast cancer (EBC): 5-year results of the prospective Phase III WSG PlanB trial.

Prognostic impact of 21 Gene Recurrence Score, IHC4, and central grade in high-risk HR+/HER2- early breast cancer (EBC): 5-year results of the prospective Phase III WSG PlanB trial.

Abstract Poster

Authors

null

Oleg Gluz

West German Study Group, Moenchengladbach, Germany

Oleg Gluz , Ulrike Nitz , Matthias Christgen , Ronald E. Kates , Michael Clemens , Stefan Kraemer , Benno Nuding , Toralf Reimer , Bahriye Aktas , Sherko Kümmel , Marianne Just , Andrea Stefek , Fatemeh Lorenz-Salehi , Petra Krabisch , Cornelia Liedtke , Christer Svedman , Steven Shak , Rachel Wuerstlein , Hans Heinrich Kreipe , Nadia Harbeck

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2016 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Breast Cancer—HER2/ER

Track

Breast Cancer

Sub Track

ER+

Clinical Trial Registration Number

NCT01049425

Citation

J Clin Oncol 34, 2016 (suppl; abstr 556)

DOI

10.1200/JCO.2016.34.15_suppl.556

Abstract #

556

Poster Bd #

44

Abstract Disclosures

Similar Posters

First Author: Jane Bayani

First Author: Julia M. Greene

First Author: Wolfgang Janni

First Author: Paul E. Goss